Results 21 to 30 of about 62,301 (266)
European Journal of Haematology, 2022 Autoimmune hemolytic anemia (AIHA) is considered a chronic disease, with an overall good prognosis. However, recent reports indicate pre‐mature mortality. Causes of death have not been evaluated previously.
D. Hansen, S. Möller, H. Frederiksen
semanticscholar +1 more source
How I treat warm autoimmune hemolytic anemia.
Blood, 2021 Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation.
W. Barcellini, B. Fattizzo
semanticscholar +1 more source
Autoimmune Hemolytic Anemia in the Pediatric Setting
Journal of Clinical Medicine, 2021 Autoimmune hemolytic anemia (AIHA) is a rare disease in children, presenting with variable severity. Most commonly, warm-reactive IgG antibodies bind erythrocytes at 37 °C and induce opsonization and phagocytosis mainly by the splenic macrophages ...
A. Voulgaridou, T. Kalfa
semanticscholar +1 more source
A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine
International Journal of Laboratory Hematology, 2021 SARS-CoV-2 mRNA vaccine made by Pfizer and BioNTech was approved by the U.S. Food and Drug Administration for use under an Emergency Use Authorization for active immunization to prevent coronavirus disease caused by severe acute respiratory syndrome ...
T. Murdych
semanticscholar +1 more source
Infectious Complications in Autoimmune Hemolytic Anemia
Journal of Clinical Medicine, 2021 Autoimmune hemolytic anemia (AIHA) may be frequently challenged by infectious complications, mainly as a result of immunosuppressive treatments administered. Furthermore, infectious agents are known triggers of AIHA onset and relapse. Although being risk
J. Giannotta +3 more
semanticscholar +1 more source
A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination
Cureus, 2021 Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation.
Sérgio Brito +6 more
semanticscholar +1 more source
Complement inhibitors to treat IgM-mediated autoimmune hemolysis
Haematologica, 2015 Complement activation in autoimmune hemolytic anemia may exacerbate extravascular hemolysis and may occasionally result in intravascular hemolysis. IgM autoantibodies as characteristically found in cold autoantibody autoimmune hemolytic anemia, in cold ...
Diana Wouters, Sacha Zeerleder
doaj +1 more source
Use of Rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas [PDF]
, 2011 The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of ...
Fozza, Claudio +1 more
core +4 more sources
Diagnostic and therapeutic considerations in idiopathic hypereosinophilia with warm autoimmune hemolytic anemia. [PDF]
, 2015 Hypereosinophilic syndrome (HES) encompasses numerous diverse conditions resulting in peripheral hypereosinophilia that cannot be explained by hypersensitivity, infection, or atopy and that is not associated with known systemic diseases with specific ...
Brys, Adam K +3 more
core +1 more source
Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders
Journal of Clinical Medicine, 2021 Anemia is a common feature of liver and bowel diseases. Although the main causes of anemia in these conditions are represented by gastrointestinal bleeding and iron deficiency, autoimmune hemolytic anemia should be considered in the differential ...
C. Bianco +3 more
semanticscholar +1 more source